RecruitingPhase 4NCT06825260

PEG3350 vs Senna After Urogyn Surgery

Polyethylene Glycol 3350 Compared With Senna After Urogynecologic Surgery A Randomized Controlled Trial


Sponsor

St. Joseph's Health, New York

Enrollment

254 participants

Start Date

Apr 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery


Eligibility

Sex: FEMALEMin Age: 18 Years

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSenna

Senna, oral, 8.6mg, 2 tablets daily (up to 4 tablets twice a day) for 7 days

DRUGPolyethylene glycol 3350

Polyethylene Glycol 3350, oral, 17g, daily for 7 days


Locations(1)

St. Joseph's Health Hospital

Syracuse, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06825260


Related Trials